Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Overview of Protein Metabolism01:21

Overview of Protein Metabolism

4.4K
Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
4.4K
Protein Absorption01:12

Protein Absorption

1.3K
Proteins in the gastrointestinal tract typically come from food, but they can also originate from disintegrated cells or secreted enzymes. In the stomach, the enzyme pepsin breaks down these proteins into polypeptides. The fragments then move into the duodenum as a semi-fluid mass called chyme. Pancreatic proteases, such as trypsin and chymotrypsin, and intestinal brush border enzymes like carboxypeptidases further dismantle the polypeptides into tripeptides, dipeptides, and free amino acids.
1.3K
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

789
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
789
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

286
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
286
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

967
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
967
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications01:25

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

1.2K
Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Justification for the use of a FODMAP diet in patients with irritable bowel syndrome: focus on small intestinal disaccharidase activity].

Terapevticheskii arkhiv·2026
Same author

[A new paradigm of the pathogenesis of primary sclerosing cholangitis associated with ulcerative colitis: microbiota and system intestine-liver. A review].

Terapevticheskii arkhiv·2026
Same author

[Radiation-induced intestinal injury].

Terapevticheskii arkhiv·2025
Same author

[Results of non-medical switching from original infliximab to its Russian biosimilar in patients with ulcerative colitis].

Terapevticheskii arkhiv·2025
Same author

[Chronic small bowel obstruction in a patient with post-radiation enteropathy. Case report].

Terapevticheskii arkhiv·2025
Same author

[Russian Cross-disciplinary Consensus on the diagnosis and treatment of spondyloarthritis associated with inflammatory bowel diseases].

Terapevticheskii arkhiv·2025

Related Experiment Video

Updated: Mar 6, 2026

Quantifying Tissue-Specific Proteostatic Decline in Caenorhabditis elegans
09:18

Quantifying Tissue-Specific Proteostatic Decline in Caenorhabditis elegans

Published on: September 7, 2021

3.3K

[Protein-losing enteropathy].

A I Parfenov1, L M Krums1

  • 1Moscow Clinical Research and Practical Center, Moscow Healthcare Department, Moscow, Russia.

Terapevticheskii Arkhiv
|March 11, 2017
PubMed
Summary
This summary is machine-generated.

Protein-losing enteropathy (PLE) is a rare intestinal disease causing edema. Diagnosis involves fecal alpha-1-antitrypsin tests, while treatment focuses on a special diet or surgery for severe cases.

More Related Videos

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.6K
Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

19.9K

Related Experiment Videos

Last Updated: Mar 6, 2026

Quantifying Tissue-Specific Proteostatic Decline in Caenorhabditis elegans
09:18

Quantifying Tissue-Specific Proteostatic Decline in Caenorhabditis elegans

Published on: September 7, 2021

3.3K
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.6K
Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

19.9K

Area of Science:

  • Gastroenterology
  • Internal Medicine
  • Clinical Diagnostics

Background:

  • Protein-losing enteropathy (PLE) is a rare but serious complication of various intestinal diseases.
  • Hypoproteinemic edema is the primary clinical manifestation of PLE.

Purpose of the Study:

  • To outline the diagnostic criteria and management strategies for protein-losing enteropathy.
  • To emphasize the importance of identifying and treating intestinal protein loss.

Main Methods:

  • Diagnosis is confirmed by measuring fecal alpha-1-antitrypsin concentration and clearance to detect protein loss.
  • Radiologic and endoscopic techniques are employed to localize the affected intestinal segment.
  • Treatment involves dietary modifications and, in severe cases, surgical intervention.

Main Results:

  • Fecal alpha-1-antitrypsin testing is crucial for diagnosing PLE.
  • Dietary management, including a fat-free diet with medium-chain triglycerides, is the primary treatment.
  • Surgical resection may be necessary for refractory cases.

Conclusions:

  • Accurate diagnosis of PLE relies on verifying intestinal protein loss.
  • A tailored dietary approach is the cornerstone of management.
  • Surgical intervention offers a therapeutic option for severe, treatment-resistant protein-losing enteropathy.